Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity.

Alleles CD4 Antigens / metabolism Cell Line, Tumor Down-Regulation Gene Knockout Techniques HIV Infections / genetics HIV-1 / genetics HLA-A Antigens / metabolism Host-Pathogen Interactions / genetics Humans Membrane Proteins / antagonists & inhibitors Mutation Polymorphism, Genetic T-Lymphocytes / metabolism Virion / metabolism Virulence / genetics Virus Internalization Virus Replication / genetics nef Gene Products, Human Immunodeficiency Virus / genetics
HIV-1 Nef elite controllers host restriction serine incorporator viral infectivity viral pathogenesis

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
05 11 2019
Historique:
received: 01 05 2018
revised: 26 07 2019
accepted: 01 10 2019
entrez: 7 11 2019
pubmed: 7 11 2019
medline: 25 9 2020
Statut: ppublish

Résumé

HIV-1 Nef enhances virion infectivity by counteracting host restriction factor SERINC5; however, the impact of natural Nef polymorphisms on this function is largely unknown. We characterize SERINC5 downregulation activity of 91 primary HIV-1 subtype B nef alleles, including isolates from 45 elite controllers and 46 chronic progressors. Controller-derived Nef clones display lower ability to downregulate SERINC5 (median 80% activity) compared with progressor-derived clones (median 96% activity) (p = 0.0005). We identify 18 Nef polymorphisms associated with differential function, including two CTL escape mutations that contribute to lower SERINC5 downregulation: K94E, driven by HLA-B

Identifiants

DOI: 10.1016/j.celrep.2019.10.007 PMID: 31693887 PMC: PMC6925589
pubmed: 31693887
pii: S2211-1247(19)31300-2
doi: 10.1016/j.celrep.2019.10.007
pmc: PMC6925589
mid: NIHMS1542670
pii:
doi:

Substances chimiques

CD4 Antigens 0
HLA-A Antigens 0
Membrane Proteins 0
SERINC5 protein, human 0
nef Gene Products, Human Immunodeficiency Virus 0
nef protein, Human immunodeficiency virus 1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1449-1457.e5

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI127263
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126617
Pays : United States

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Nat Med. 1996 Mar;2(3):338-42
pubmed: 8612235
J Virol. 1994 May;68(5):2906-14
pubmed: 8151761
Cell Commun Signal. 2012 Dec 10;10(1):39
pubmed: 23227982
Traffic. 2016 Sep;17(9):976-96
pubmed: 27161574
Antimicrob Agents Chemother. 2004 May;48(5):1652-63
pubmed: 15105117
J Virol. 2008 Sep;82(18):9216-27
pubmed: 18614631
Nature. 2015 Oct 8;526(7572):212-7
pubmed: 26416734
J Virol. 2018 Dec 10;93(1):
pubmed: 30305354
Virology. 2018 Feb;515:52-65
pubmed: 29268082
PLoS Pathog. 2007 Jul;3(7):e94
pubmed: 17616974
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Science. 1995 Nov 10;270(5238):988-91
pubmed: 7481804
N Engl J Med. 1995 Jan 26;332(4):228-32
pubmed: 7808489
J Virol. 1998 Apr;72(4):2855-64
pubmed: 9525605
J Virol. 2008 Dec;82(24):12585-8
pubmed: 18842727
Nature. 1998 Jan 22;391(6665):397-401
pubmed: 9450757
Retrovirology. 2013 Jan 07;10:1
pubmed: 23289738
J Virol. 2018 May 14;92(11):
pubmed: 29514909
J Neuroimmune Pharmacol. 2011 Jun;6(2):230-46
pubmed: 21336563
Immunity. 2007 Sep;27(3):406-16
pubmed: 17892849
J Virol. 2016 Nov 14;90(23):10915-10927
pubmed: 27681140
Cell Logist. 2011 May;1(3):90-102
pubmed: 21922073
J Virol. 2015 Dec 30;90(6):2993-3002
pubmed: 26719277
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
J Virol. 2017 Jan 31;91(4):
pubmed: 27928004
J Biol Chem. 2017 Apr 7;292(14):6014-6026
pubmed: 28179429
Nature. 2015 Oct 8;526(7572):218-23
pubmed: 26416733
Cell Host Microbe. 2016 Sep 14;20(3):381-391
pubmed: 27631701
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5705-5714
pubmed: 30842281
J Virol Methods. 2006 Feb;131(2):134-42
pubmed: 16182382
J Virol. 1993 Aug;67(8):4639-50
pubmed: 8043040
Gene Ther. 1999 May;6(5):715-28
pubmed: 10505094
Nature. 1991 Apr 11;350(6318):508-11
pubmed: 2014052
PLoS Med. 2006 Oct;3(10):e403
pubmed: 17076553
J Virol. 1986 Nov;60(2):754-60
pubmed: 3490583
J Immunol Methods. 2015 Nov;426:104-13
pubmed: 26319395
Cell. 1994 Mar 11;76(5):853-64
pubmed: 8124721
Science. 1989 Dec 22;246(4937):1629-32
pubmed: 2531920
J Exp Med. 1994 Jan 1;179(1):101-13
pubmed: 8270859
J Virol. 2001 Apr;75(8):3657-65
pubmed: 11264355
Cell. 1991 May 17;65(4):651-62
pubmed: 2032289
J Virol. 2001 Feb;75(4):1672-80
pubmed: 11160665
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Curr HIV Res. 2011 Oct;9(7):496-504
pubmed: 22103833
J Virol. 2006 Feb;80(4):1837-49
pubmed: 16439540
Bioinformatics. 2005 Mar 1;21(5):676-9
pubmed: 15509596
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
J Virol. 2009 Aug;83(16):8289-92
pubmed: 19474095
J Virol. 2017 Jul 27;91(16):
pubmed: 28615199
J Virol. 2000 Sep;74(18):8358-67
pubmed: 10954535
MBio. 2019 Jun 11;10(3):
pubmed: 31186327
Biotechniques. 2006 Jan;40(1):91-100
pubmed: 16454046

Auteurs

Steven W Jin (SW)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.

Nirmin Alsahafi (N)

Centre de Recherche du CHUM, Montreal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.

Xiaomei T Kuang (XT)

Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.

Shayda A Swann (SA)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.

Mako Toyoda (M)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Heinrich Göttlinger (H)

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.

Bruce D Walker (BD)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Cambridge, MA, USA.

Takamasa Ueno (T)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Andrés Finzi (A)

Centre de Recherche du CHUM, Montreal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada; Department of Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.

Zabrina L Brumme (ZL)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.

Mark A Brockman (MA)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. Electronic address: mark_brockman@sfu.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Allèles › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Antigènes CD4 › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation négative › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Ciblage de gène › Techniques de knock-out de gènes › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes HLA › Antigènes HLA-A › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Phénomènes biologiques › Interactions hôte-microbes › Interactions hôte-pathogène › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Structures virales › Virion › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Phénomènes microbiologiques › Virulence › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Pénétration virale › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Natural HIV-1 Nef Polymorphisms Impair SERINC5...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales régulatrices ou accessoires › Produits du gène nef › Produits du gène nef du virus de l'immunodéficience humaine › Natural HIV-1 Nef Polymorphisms Impair SERINC5...